Search Follow us

Newron Pharmaceuticals (NWRN)

Business description

Newron is a CNS-focused biotech. Xadago (partnered with Zambon, US WorldMeds, Meiji Seika, Sequirus) for PD has been launched in Europe and the US. Other pipeline assets include Sarizotan (Phase III for RS) and Evenamide (Phase II for schizophrenia).

Back on track

QuickView | Pharmaceutical & healthcare | 09/11/2016

Xadago (safinamide) for Parkinson’s disease (PD) is back on track in the US as the FDA has informed the company and its partners, Zambon and US WorldMeds, that no further clinical studies will be required following the 29 March complete response letter. Newron resubmitted Xadago’s NDA in September; US PDUFA date is set for 21 March 2017. In Europe the Xadago roll-out is ongoing, with commercial partner Zambon having launched the product in multiple European countries. We value Newron at CHF494m or CHF34.7/share.

Edison's research is freely available. We will never ask for your credit card details and you do not need to register. By downloading this research you are agreeing to our terms and conditions, which you can read in full here.

Stock data

Market cap.CHF243.4m
Last closeCHF13.640
High / Low (52 weeks)CHF20.5 / CHF8.2
Stock market listingSW
Forecast net cash (€m)47.9
Forecast gearing ratio (%)N/A
TeamHealthcare
SectorPharmaceutical & healthcare

Price performance

%1m3m12m
Actual16.055.0(32.8)
Relative *13.654.9(31.2)

* % Relative to local index

Company news